Summary of research status of vascular intervention for primary liver cancer

Abstract

Abstract: In 1978, Professor Yamada summarized his many years of experience in interventional therapy and pioneered the concept of transcatheter arterial chemoembolization (TACE), which marked a new stage of transvascular inter-ventional therapy. Thanks to the innovation of interventional devices and advances in treatment concepts in recent years, new local treatment modalities such as drug-eluting bead TACE (DEB-TACE) and transarterial radioembolization have emerged on the basis of traditional interventional therapy. Since 2018, with the advent of the era of targeted and immunotherapy, the comprehensive treatment model of transvascular interventional therapy combined with targeted and immunotherapy has gained widespread esteem and application, and the corresponding research advances are accelerating to change the treatment norms of liver cancer.

Key words: Primary liver cancer, Vascular intervention, Locoregional therapies, Research status

Fan Weijun. Summary of research status of vascular intervention for primary liver cancer[J]. Electronic Journal of Liver Tumor, 2023, 10(3): 27-30.

References

[1] LLOVET J M, REAL M I, MONTAñA X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial[J]. Lancet, 2002, 359(9319): 1734-1739.
[2] LO C M, NGAN H, TSO W K, et al.Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J]. Hepatology, 2002, 35(5): 1164-1171.
[3] BOULIN M, GUIU S, CHAUFFERT B, et al.Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma[J]. Anticancer Drugs, 2011, 22(8): 741-748.
[4] KATSANOS K, KITROU P, SPILIOPOULOS S, et al.Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials[J]. PLoS One, 2017, 12(9): e0184597.
[5] TAKAYASU K, ARII S, IKAI I, et al.Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis[J]. AJR Am J Roentgenol, 2010, 194(3): 830-837.
[6] HU J, ALBADAWI H, CHONG B W, et al.Advances in Biomaterials and Technologies for Vascular Embolization[J]. Adv Mater, 2019, 31(33): e1901071.
[7] CHOI B I, KIM H C, HAN J K, et al.Therapeutic effect of transcatheter oily chemoembolization therapy for encapsulated nodular hepatocellular carcinoma: CT and pathologic findings[J]. Radiology, 1992, 182(3): 709-713.
[8] OKUSAKA T, OKADA S, UENO H, et al.Evaluation of the therapeutic effect of transcatheter arterial embolization for hepatocellular carcinoma[J]. Oncology, 2000, 58(4): 293-299.
[9] 中国医师协会介入医师分会临床诊疗指南专委会. 中国肝细胞癌经动脉化疗栓塞(TACE)治疗临床实践指南(2021年版)[J]. 中华医学杂志, 2021, 101(24): 1848-1862.
[10] 仲斌演, 王万胜, 朱海东. 肝细胞癌经动脉化疗栓塞抵抗及后续治疗专家共识[J]. 介入放射学杂志, 2022, 31(11): 1039-1044.
[11] KUDO M, UESHIMA K, YOKOSUKA O, et al.Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2018, 3(6): 424-432.
[12] TZORACOLEFTHERAKIS E E, SPILIOTIS J D, KYRIAKOPOULOU T, et al.Intra-arterial versus systemic chemotherapy for non-operable hepatocellular carcinoma[J]. Hepatogastroenterology, 1999, 46(26): 1122-1125.
[13] LYU N, WANG X, LI J B, et al.Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase iii trial (FOHAIC-1)[J]. J Clin Oncol, 2022, 40(5): 468-480.
[14] LI Q J, HE M K, CHEN H W, et al.Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial[J]. J Clin Oncol, 2022, 40(2): 150-160.
[15] LEWANDOWSKI R J, GABR A, ABOUCHALEH N, et al.Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma[J]. Radiology, 2018, 287(3): 1050-1058.
[16] GARIN E, TSELIKAS L, GUIU B, et al.Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2021, 6(1): 17-29.
[17] LU J, GUO J H, ZHU H D, et al. Safety and efficacy of irradiation stent placement for malignant portal vein thrombus combined with transarterial chemoembolization for hepatocellular carcinoma: a single-center experience [J]. J Vasc Interv Radiol, 2017, 28(6): 786-794.e3.
[18] YU T Z, ZHANG W, LIU Q X, et al.Endovascular brachytherapy combined with portal vein stenting and transarterial chemoembolization improves overall survival of hepatocellular carcinoma patients with main portal vein tumor thrombus[J]. Oncotarget, 2017, 8(7): 12108-12119.
[19] IEZZI R, POMPILI M, POSA A, et al.Combined locoregional treatment of patients with hepatocellular carcinoma: State of the art[J]. World J Gastroenterol, 2016, 22(6): 1935-1942.